CDC20 and endometrial cancer: These data show that the higher expression of CDC20 (OS, HR = 1.863, 95% CI 1.065–3.195, p = 0.031; PFS, HR = 1.598, 95% CI 1.063–2.759, p = 0.032) and CCNA2 (OS, HR = 1.740, 95% CI 1.034–3.273, p = 0.040; PFS, HR = 1.480, 95% CI 0.955–2.536, p = 0.082) were associated with poor prognosis in endometrial cancer patients.